单药口服替吉奥与单药吉西他滨对中晚期胰腺癌的综合疗效比较

Comparison of Comprehensive Efficacy of Gio Oral Monotherapy and Single-agent Gemcitabine for Advanced Pancreatic Cancer

目的探究单药口服替吉奥与单药吉西他滨对中晚期胰腺癌的综合疗效。方法选取中晚期胰腺癌患者92例为研究对象,针对患者的临床资料进行了回顾性的比较研究。结果 (1)替吉奥组46例患者中,完全缓解4例,部分缓解10例,稳定16例,进展16例,有效率为30.4%;吉西他滨组46例患者中,完全缓解4例,部分缓解9例,稳定15例,进展18例,有效率为28.3%。2组临床治疗有效率组间比较,差异均无统计学意义;(2)替吉奥组46例患者6个月生存患者22例,1年的生存患者16例,2年生存患者4例;吉西他滨组46例患者6个月生存患者23例,1年的生存患者15例,2年生存患者3例。2组不同时点的生存率水平相当,组间差异无统计学意义;(3)2组患者化疗前后CEA和CA-199水平差异不大,且组间差异无统计学意义;(4)2组不良反应发生率无显著差异。结论单药口服替吉奥与单药吉西他滨对中晚期胰腺癌的综合疗效相当,近远期综合治疗效果差异不明显。

Objective To explore the comprehensive efficacy of Gio oral monotherapy and single-agent gemcitabine for advanced pancreatic cancer. Methods 92 cases with advanced pancreatic cancer were chosen. The clinical data of the patients were retrospectively studied. Results （ 1 ） In the Gio group of 46 patients,4 cases were of complete remission, partial remission 10 cases,no change 16 cases,progress 16 cases,effective 14 cases. In the gemcitabine group of 46 patients ,4 cases were of complete remission, partial remission 9 cases, no change 15 cases, 18 cases were of progress, effective 13 cases. The treatment efficiency rates of the 2 groups had no statistical differences. （2） In the Gio group of 46 patients, 6-month survival was 22 cases , 1-year survival was 16 cases ,2-year survival was 4 cases. In the gemcitabine group of 46 patients ,6-month survival was of 23 patients, 1- year survival was 15 cases, and 2-year survival was of 3 patients. The survival rates at different time of the 2 groups had no significant difference. （3） CEA and CA-199 before and after treatment between the 2 groups had no significant difference. （4） Adverse reactions between the 2 groups had no significant difference. Conclusion The comprehensive efficacy of single-agent oral Gio and monotherapy with gemcitabine for advanced pancreatic cancer are similar, short-term and long-term comprehensive efficacy between the 2 groups have no significant difference.